Počet záznamov: 1
PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer
- PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer / Y. Zhang ... [et al.] . Neoplasma : journal of experimental and clinical oncology. - ISSN 0028-2685 . - Vol. 61, no. 4 (2014), s. 461-467 : ilustr., obr., tab.
- C 720
článok
Počet záznamov: 1